PCM
RLAY icon

Prelude Capital Management’s Relay Therapeutics RLAY Stock Holding History

Prelude Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,899
Closed -$616K – 1488
2026
Q1 		$616K Buy
+61,899
New +$554K 0.05% 434
2025
Q4 		– Sell
-19,700
Closed -$103K – 1518
2025
Q3 		$103K Buy
19,700
+3,100
+19% +$11.8K 0.01% 1052
2025
Q2 		$57.4K Sell
16,600
-4,600
-22% -$13.7K 0.01% 955
2025
Q1 		$55.5K Sell
21,200
-275,965
-93% -$1.08M ﹤0.01% 1090
2024
Q4 		$1.22M Buy
297,165
+187,253
+170% +$1.02M 0.08% 326
2024
Q3 		$778K Buy
+109,912
New +$821K 0.05% 458

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Prelude Capital Management's RLAY Position: Q2 2026 in Review

Prelude Capital Management sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 61,899 shares — an estimated $616K sold.

Prelude Capital Management first reported a position in RLAY in Q3 2024 and held it in 6 quarters. The position peaked at $1.22M in Q4 2024. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Prelude Capital Management reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 61,899 Relay Therapeutics shares in Q2 2026, an estimated $616K.
  • Prelude Capital Management first reported a position in Relay Therapeutics in Q3 2024 and held it in 6 quarters.
  • Prelude Capital Management's Relay Therapeutics position peaked at $1.22M in Q4 2024.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.